---
title: 'Pembrolizumab versus ipilimumab for advanced melanoma: 10-year follow-up of
  the phase III KEYNOTE-006 study'
date: '2024-09-21'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/39306585/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&fc=20220326224207&ff=20240922200412&v=2.18.0.post9+e462414
source: heidelberg[Affiliation]
description: 'CONCLUSIONS: These results confirm that pembrolizumab provides long-term
  survival benefits in advanced melanoma, supporting it as a standard of care in this
  ...'
disable_comments: true
---
CONCLUSIONS: These results confirm that pembrolizumab provides long-term survival benefits in advanced melanoma, supporting it as a standard of care in this ...